
    
      This is a single arm phase II trial to test the efficacy and feasibility of new sequential
      intensive chemo and transplantation approach for refractory leukemia. Patients with
      refractory acute myeloid or lymphoblastic leukemia are enrolled in this trial. Patients will
      received intensive chemotherapy including Fludarabine, cytarabine and idarubicin as
      (FLAG-IDA). Seven days after the chemotherapy, sequential transplantation conditioning
      regimen as fludarabine and busulfan will be given.
    
  